The Immunogenicity and Immune Tolerance of Pluripotent Stem Cell Derivatives

1The successful establishment of human embryonic stem cells (hESCs) from the inner cell mass of the human blastocyts has opened up a new era in regenerative medicine. Significant progress has been achieved in developing protocols to differentiate hESCs into various lineages of biologically active cells such as neural cells, pancreatic β cells, retinal pigmented epithelial (RPE) cells, cardiomyocytes, and hepatocytes. Three of such hESC-derived cells have entered clinical trial to treat macular degeneration, spinal cord injury, and type 1 diabetes. In addition, these clinical trials have provided promising data on the safety and efficacy of hESC-based cell therapy of macular degeneration, further supporting the great potential of the clinical application of hESC. However, one of the main bottlenecks that hinder the clinical development of hESC-based therapy is the allogeneic immune rejection by the recipient. While current immune suppression regimen can effectively prevent allogeneic immune rejection, the persistent use of immune suppressants is toxic to patients, and can greatly increase the risk of infection and cancer, especially in patients infected with cytomegalovirus and the herpes viruses. In addition, immune suppressants are toxic to some of the hESC-derived progenitor cells.

2The development of induced pluripotent stem cells (iPSCs) by reprogramming somatic cells into pluripotent state with defined transcriptional factors has provided another source of PSC for human cell therapy. When compared with hESC-based cell therapy, iPSCs were thought to provide certain advantages, including the lack of ethic concerns and immune rejection by the recipient. However, recent studies have demonstrated the increased genomic instability, epigenetic abnormality, and immunogenicity of iPSCs, raising safety concerns of iPSC-based cell therapy. Therefore, to improve the feasibility of iPSC-based therapy, it is important to understand the underlying reprogramming mechanism and develop strategies to minimize these safety concerns.

3The polymorphic major histocompatibility complex (MHC) molecules are distinct between individuals, leading to the massive T cell-mediated immune response and rejection of the transplanted allogeneic cells. There are two classes of MHC molecules, MHC class I molecules that are expressed on most of the nucleated cells and MHC class II molecules that are expressed primarily on antigen presenting cells. MHC class I molecules are required to activate CD8+ cytotoxic T cells that can destroy the target cells, and MHC class II molecules are required to activate CD4+ helper T cells that are critical to activate other immune cells including cytotoxic T cells. In addition, certain cell types lacking the expression of MHC class I molecules such as stem cells and cancer cells are rejected by natural killer (NK) cells.

4While mouse ESCs do not express detectable MHC Class I and Class II molecules, hESCs express MHC Class I molecules but not MHC Class II molecules, and hESCs cannot directly activate T cells in vitro and in vivo. However, hESCs can be immune rejected by various mechanisms after transplantation. First, allogeneic NK cells can eliminate mouse and human ESCs in vitro. Second, while ESCs do not directly activate allogeneic T cell through the interaction between allogeneic MHC molecules and TCR, ESCs express immunogenic antigens such as MHC Class I molecules and Oct4 that can indirectly activate T cells through antigen presenting cells. Third, after transplantation, both mouse and human ESCs cannot maintain the pluripotent state and will undergo spontaneous differentiation into various cell types that express MHC molecules, leading to robust T-dependent allogeneic rejection. Therefore, hESCs and their derivatives will be immune rejected when transplanted into allogeneic recipients.

5While it has been suggested that ESCs might have immune modulatory functions in treating certain diseases such as myocardial infarction, ESCs pose a serious teratoma risk after transplantation and thus are unlikely to be used directly in therapy. Therefore, the major effort should be devoted to understanding the allogeneic immune responses to hESC-derived cells that have no teratoma risk. There has been limited progress in this area of research due to the lack of robust animal models to study the human immune responses to hESC-derived cells. Recent application of humanized mice reconstituted with functional human immune system, which are generated by transplanting human fetal thymus and CD34+ fetal liver cells, has made this research more feasible. In support of this notion, recent studies demonstrated that the humanized mice could mount vigorous allogeneic immune rejection of hESC-derived cells.

6The breakthrough of induced pluripotency to reprogram somatic cells from patients into PSC has raised the possibility that the cells derived from patient-specific iPSCs are autologous and thus will not be immune rejected by the patient. However, hiPSCs can be rejected by allogeneic and autologous NK cells. In addition, accumulating data have demonstrated that cells derived from iPSCs can be immunogenic to the autologous immune system. Using an inbred C57/BL6 (B6) transplantation mouse model, Zhao et al. demonstrated that cells derived from B6 iPSCs can activate syngeneic T-dependent immune responses due to the deregulated expression of immunogenic proteins such as the tumor antigen Hormad1. This conclusion is supported by a following study, which also demonstrated that the endothelial cells derived from B6 iPSCs are immune tolerated by B6 mice. However, the iPSC-derived endothelial cells express high levels of immune suppressive cytokines such as IL-10 and are immune rejected in B6 mice when treated with anti-IL-10 antibody, supporting the notion that these iPSC-derived endothelial cells are intrinsically immunogenic. In addition, cardiomyocytes derived from B6 iPSCs are highly immunogenic when transplanted into the B6 mice subcutaneously. In the same study, the authors derived GFP+ skin tissue from B6 chimeric mice generated by injecting GFP-expressing B6 iPSCs into B6 blastocyts and found no immune rejection when the GFP+ skin tissue was grafted to new B6 mice. However, these B6 iPSC-derived skin tissues have already been preselected by the B6 immune system in the chimeric mice, and thus the skin graft will not be rejected by B6 immune system when transplanted onto new B6 mice. In support of this notion, GFP is a foreign protein and immunogenic to B6 mice when expressed in the skin, and GFP-expressing skin tissues of GFP transgenic B6 mice are immune rejected when grafted to the B6 mice.

7Several recent studies have argued that iPSC-derived cells are not immunogenic to the isogenic or autologous immune system. By transplanting cells derived from B6 iPSCs under the kidney capsule of B6 mice, Guha et al. concluded that various lineages of iPSC-derived cells exhibit no immunogenicity. In addition, the transplantation of iPSC-derived neural cells in the brain of autologous monkeys leads to minimum immune response. To resolve this apparent discrepancy, a recent study showed that the lack of immunogenicity of B6-derived iPSCs transplanted under the kidney capsule is due to the absence of functional antigen presenting cells in the kidney, and the cotransplantation of B6 iPSC-derived cells with functional B6 dendritic cells under the kidney capsule leads to robust immune rejection. Therefore, the presence of functional antigen presenting cells at the transplantation site is required to reveal the immunogenicity of iPSC-derived cells. In further support of the conclusion that iPSC-derived cells can be immunogenic, using a humanized mouse model reconstituted with human immune system, Zhao et al. demonstrated the differential immunogenicity of human iPSC-derived cells. In this context, iPSC-derived smooth muscle cells are highly immunogenic to the autologous immune system due to the deregulated expression of immunogenic proteins, but iPSC-derived RPE cells are not immunogenic to the autologous immune system even when transplanted into smooth muscle. Importantly, the lack of immunogenicity of iPSC-derived RPE cells has been recapitulated in the only one treated patient in the clinical trial to use autologous iPSC-derived RPE cells to treat macular degeneration.

8There are several mechanisms to explain the immunogenicity of iPSCs. First, compared to ESCs, iPSCs are epigenetically abnormal and inherited epigenetic signature of parental cells. The epigenetic abnormalities could explain the abnormal expression of immunogenic proteins expressed during the differentiation of iPSCs but not ESCs. The impact of this epigenetic mechanism on the deregulated expression of immunogenic proteins could be cell lineage specific as observed in the differentiation of hiPSCs into RPEs and smooth muscle cells. Second, somatic coding mutations are detected in all iPSC lines tested, and the protein coding mutations can create new immunogenic determinants like the tumor antigens developed in cancer cells. Third, the genomic translocation detected in the iPSCs will create fusion proteins and new immunogenic determinants. Therefore, in addition to the immunogenicity of iPSC-derived cells, a more serious safety concern of the iPSC-based cell therapy is the genomic instability of iPSCs that can greatly increase cancer risk. In support of this notion, the first clinical trials of iPSC-based cell therapy was terminated after the enrollment of the first patient due to the discovery of coding mutations in cancer related genes in the iPSCs reprogrammed from the somatic cells of the second patient. This cancer concern poses a serious bottleneck for developing individualized cell therapy using patients’ own iPSC. Instead, future effort will be devoted to establish genetically stable iPSC cell bank, and the iPSC line with the best match to the patient’s HLA will be used for cell therapy. In this context, the clinic development of allogeneic iPSC will face the same challenge of immune rejection as hESCs.

9While immune suppressant regimen can effectively suppress allogeneic immune responses, the persistent use of immune suppressants will significantly increase the risk of infection and cancer, especially in the majority of the population with Cytomegalovirus infection. In addition, the immune suppressants are toxic to some hESC-derived cells such as neural progenitor cells. Therefore, to realize the potential of hESC-based therapy, it is important to develop safe and effective immune tolerance strategy of allogeneic hESC-derived cells.

10Allogeneic immune rejection is primarily mediated by T cell-dependent immune responses. Previous studies have demonstrated that standard immunosuppressive drug regimens can significantly reduce the immune response to prolong the survival of hESC-derived xenografts but cannot eventually prevent immune rejection. Based on our knowledge of the pathways critical for T-cell activation, it is possible to induce immune tolerance of hESC-derived allogeneic cells by disrupting the T cell costimulatory pathways, such as CD28-CD80/CD86 and CD40–CD40L pathways. PD-L1 also plays a central role in maintaining T cell anergy and preventing autoimmunity. PD-L1 (B7-H1, CD274) interacts with programmed cell death 1 (PD-1), which is an inhibitory receptor expressed on activated T cells, NK cells, and B cells, and this interaction leads to negative regulation of lymphocyte activation, and PD-1 is required for the induction of T-cell tolerance by dendritic cells. Therefore, it is possible to develop immune tolerance strategy by modulating these costimulatory and inhibitory pathways.

11A recent study has shown that treatment of mice with cytotoxic T lymphocyte antigen 4-Ig (CTLA4-Ig), which binds to the B7 family of costimulatory molecules CD80 and CD86 with higher affinity and avidity than CD28, and anti-CD40L blocking CD40-CD40L pathway not only prolonged hESC-derived pancreatic endoderm graft survival but also resulted in the establishment of immune tolerance of the xeno-immune system. A similar study also showed that the blockade of costimulatory pathways with antibodies significantly prolonged the engraftment of cells derived from human ESCs and iPSCs in mice without inhibiting the ability of the recipient to respond to other foreign antigens. However, in contrast to the naive T cells of a mouse model, up to 50% of alloreactive T cells in a human receiving transplants may display a memory phenotype, and the allogeneic immune tolerance of mouse immune system can be achieved more easily than human immune system. Therefore, the immune tolerance strategy developed in mouse models must be re-evaluated in the context of human immune system.

12To address this bottleneck, recent studies have employed humanized mice reconstituted with human immune system to study human immune responses to cells derived from hPSCs. The human immune system of humanized mice can robustly reject allogeneic cells derived from human embryonic stem cells (hESCs), and thus can be used to vigorously test immune tolerance strategy. Using humanized mice, it was demonstrated that the expression of CTLA4-Ig and PD-L1 in the cells derived from genetically modified hESCs can effectively protect these cells from allogeneic human immune responses without inducing systemic immune suppression. Neither the expression of CTLA4-Ig nor PD-L1 alone is sufficient to provide immune protection, consistent with human clinical data. Because the CTLA4-Ig/PD-L1-expressing cells are immune evasive, they are susceptible to infection and cancer. To minimize the risk, the co-expression of the suicidal thymidine kinase gene in these cells enables the efficient elimination of the graft with FDA-approved TK-targeting drug. These studies supported the feasibility to develop safe and effective strategy to protect hESC-derived allografts from immune rejection.

13In addition to the modulation of the T cell costimulatory and inhibitory pathways, other strategies have been explored to confer immune protection of allogeneic hESC-derived allografts. One such attempt is to reduce the immunogenicity of hESC-derived cells by disrupting the expression of MHC molecules that elicit allogeneic T-cell responses. For example, knockdown of both HLA class I and class II in hESC could provoke T-cell ignorance in vitro and protection from xenogeneic immune rejection in vivo. Disruption of MHC class II transactivator in hESCs leads to the silencing of HLA class II expression in differentiated cells, such genetic modification could confer protection from the allogeneic helper T cells. While the immune evasive properties of these cells lacking HLA I and II molecules have been confirmed in vitro and in mice, they remain to be evaluated in the context of a human immune system.

14Despite their potential in curing major diseases and the encouraging clinical trial data, one of the key challenges for hPSC-based therapy is the immune rejection by the recipient. With extensive data of the transplantation immunology in mice and the accumulating data on the human immune responses to hESC-derived allografts in humanized mice, it has become apparently feasible to develop safe and effective strategies to induce graft-specific immune tolerance in the near future. Such achievement will greatly facilitate the clinic development of hPSC-based therapy.

15All authors listed have made substantial, direct, and intellectual contribution to the work and approved it for publication.

16The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.